SCHEMBL1775945

SCHEMBL1775945

CC(=O)O[C@H]1[C@H](OCc2ccccc2)[C@@H](OCc2ccccc2)C(O)O[C@@H]1COCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.48
TSHR P16473 1/20 0.47
TACR2 P21452 3/20 0.47
PTPN1 P18031 7/20 0.46
CDC25B P30305 5/20 0.46
LMNA P02545 2/20 0.44
PTPN2 P17706 3/20 0.44
PTPN11 Q06124 3/20 0.44
PTPN6 P29350 2/20 0.44
BCHE P06276 1/20 0.44
KMT2A Q03164 1/20 0.43
TNF P01375 1/20 0.43
SSTR1 P30872 1/20 0.43
SSTR2 P30874 1/20 0.43
SSTR4 P31391 1/20 0.43
SSTR3 P32745 1/20 0.43
SSTR5 P35346 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1775948 1.00 NT5E (0.48) NT5ETSHRTACR2PTPN1CDC25B
SCHEMBL22073055 0.98 TSHR (0.50) NT5ETSHRTACR2PTPN1CDC25B
SCHEMBL2482599 0.95 NT5E (0.51) NT5ETSHRTACR2PTPN1CDC25B
SCHEMBL18744567 0.95 NT5E (0.51) NT5ETSHRTACR2PTPN1CDC25B
SCHEMBL20295300 0.95 NT5E (0.51) NT5ETSHRTACR2PTPN1CDC25B
SCHEMBL4181388 0.95 NT5E (0.51) NT5ETSHRTACR2PTPN1CDC25B
SCHEMBL8225871 0.95 NT5E (0.51) NT5ETSHRTACR2PTPN1CDC25B
SCHEMBL18241576 0.95 NT5E (0.51) NT5ETSHRTACR2PTPN1CDC25B
SCHEMBL19731824 0.95 NT5E (0.51) NT5ETSHRTACR2PTPN1CDC25B
SCHEMBL22073758 0.94 GJB2 (0.46) NT5ETSHRTACR2PTPN1CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943584-B2 Medicinal composition containing diabetes remedy SANKYO COMPANY, LIMITED (JP) 2011-05-17 US disclosed
EP-1589023-B1 OLIGOSACCHARIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7632930-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2009-12-15 US disclosed
US-20080194495-A1 Oligosaccharide Derivative HONDA TAKESHI 2008-08-14 US disclosed
US-7361744-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2008-04-22 US disclosed
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy SANKYO COMPANY, LIMITED (JP) 2008-02-14 US disclosed
EP-1792620-A1 MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY Sankyo Company, Limited (JP) 2007-06-06 EP disclosed
US-20060025350-A1 Oligosaccharide derivative SANKYO COMPANY, LIMITED (JP) 2006-02-02 US disclosed
EP-1589023-A1 OLIGOSACCHARIDE DERIVATIVE Sankyo Company, Limited (JP) 2005-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy DPP4, IAPP, AMY2A NT5E 1662/4885TSHR 2401/4885TACR2 3957/4885
US-20060025350-A1 Oligosaccharide derivative MAN1B1, FUT6, MAN2A1 NT5E 3836/4885TSHR 1874/4885TACR2 2977/4885
US-20080194495-A1 Oligosaccharide Derivative MAN1B1, FUT6, MAN2A1 NT5E 3836/4885TSHR 1874/4885TACR2 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.